Description: Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge City, China.
Home Page: www.newlandpharma.com
East side of the southern section of Weiwu Road
Changge City,
461500
China
Phone:
86 37 4610 5083
Officers
| Name | Title |
|---|---|
| Mr. Luwei Zhang | GM & Director |
| Mr. Chao Liu | Deputy GM & Director |
Exchange: SHE
Country: CN : China
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 26.2069 |
| Price-to-Book MRQ: | 2.898 |
| Price-to-Sales TTM: | 6.0935 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1010 |